---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059613"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:24:30.165948+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kyverna Q1 net loss $26.7M; cash $369.8M; treated 30 patients cumulatively

## Summary
- Net loss of $26.7M ($1.12 per share) vs net loss of $11.1M ($12.10 per share) in Q1 2023.
- Cash, cash equivalents and marketable securities $369.8M as of March 31, 2024, including $336.2M net IPO proceeds.
- Treated 30 patients cumulatively with KYV-101: 8 myasthenia gravis, 7 lupus nephritis, 4 multiple sclerosis.
- KYV-101 granted FDA Orphan Drug Designation for myasthenia gravis; upcoming data at EULAR, ECTRIMS, ACR.
- Net cash used in operations $25.5M in Q1 2024 vs $11.5M in Q1 2023.

## SEC filing metadata
- accession: 0000950170-24-059613
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017024059613/0000950170-24-059613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017024059613/kytx-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059613
- JSON: https://secwatch.observer/filing/0000950170-24-059613.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059613.txt

## Key facts
- Earnings Releases
  Kyverna Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income a net loss of $26.7 million, EPS a net loss per common share of $1.12.
  - Period: the first quarter ended March 31, 2024
  - Net income: a net loss of $26.7 million
  - EPS: a net loss per common share of $1.12
  - Result: reported results
  source text: For the quarter ended March 31, 2024, the company reported a net loss of $26.7 million, or a net loss per common share of $1.12
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000095017024059613/0000950170-24-059613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.